Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 12/20 | 0.55 |
| ▸ | PDE4A | P27815 | 11/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.55 |
| ▸ | PDE5A | O76074 | 3/20 | 0.54 |
| ▸ | PDE1A | P54750 | 1/20 | 0.54 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.54 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825638 | 0.92 | PDE4D (0.64) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL4824224 | 0.91 | PDE4A (0.61) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL4824218 | 0.91 | PDE4A (0.61) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL4825921 | 0.85 | PDE4B (0.69) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL4825447 | 0.82 | PDE4B (0.56) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL4826823 | 0.81 | PDE4A (0.59) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL8269320 | 0.79 | PDE4D (0.61) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL8499395 | 0.79 | PDE4A (0.72) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL8271321 | 0.79 | PDE4A (0.72) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL8269312 | 0.79 | PDE4A (0.72) | PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019030-B2 | Cyano and carboxy derivatives of substituted styrenes; inhibitors of tumor necrosis factor alpha, nuclear factor kappa B, and phosphodiesterase | CELGENE CORPORATION (US) | 2006-03-28 | — | — | US | disclosed |
| US-20040019106-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019106-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | PDE4D 80/4885PDE4A 22/4885PDE4B 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.